{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:32:53Z","timestamp":1771461173579,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T00:00:00Z","timestamp":1505433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To identify current UK practice with regards to provision of blood components for cytomegalovirus (CMV)\u2010seronegative, potential, allogeneic stem cell recipients of seronegative grafts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>Infection with CMV remains a major cause of morbidity and mortality after allogeneic stem cell transplantation (aSCT). CMV transmission has been a risk associated with the transfusion of blood components from previously exposed donors, but leucocyte reduction has been demonstrated to minimise this risk. In 2012, the UK Advisory Committee for the Safety of Tissues and Organs (SaBTO) recommended that CMV\u2010unselected components could be safely transfused without increased risk of CMV transmission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We surveyed UK aSCT centres to establish current practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifteen adult and seven paediatric centres (75%) responded; 22\u00b77% continue to provide components from CMV\u2010seronegative donors. Reasons cited include the continued perceived risk of CMV transmission by blood transfusion, its associated morbidity and concerns regarding potential for ambiguous CMV serostatus in seronegative potential transplant recipients due to passive antibody transfer from CMV\u2010seropositive blood donors, leading to erroneous donor\/recipient CMV matching at transplant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The survey demonstrated a surprisingly high rate (22.7%) of centres continuing to provide blood components from CMV\u2010seronegative donors despite SaBTO guidance.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tme.12461","type":"journal-article","created":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T06:32:40Z","timestamp":1505457160000},"page":"444-450","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Provision of cellular blood components to CMV\u2010seronegative patients undergoing allogeneic stem cell transplantation in the UK: survey of UK transplant centres"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2263-3223","authenticated-orcid":false,"given":"S.","family":"Morton","sequence":"first","affiliation":[{"name":"Transfusion Medicine NHS Blood and Transplant  Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Peniket","sequence":"additional","affiliation":[{"name":"Department of Haematology Oxford University Hospitals  Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Malladi","sequence":"additional","affiliation":[{"name":"Clinical Haematology University Hospitals Birmingham  Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. F.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Transfusion Medicine NHS Blood and\u00a0Transplant  Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,9,15]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"Advisory Committee on the Safety of Blood Tissues and Organs (SaBTO)(2012)Report of the cytomegalovirus steering group. URLhttps:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/215126\/dh_132966.pdf(Accessed 9\/2\/15) https:\/\/doi.org\/10.1007\/s00411\u2010011\u20100397\u20102."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12257"},{"key":"e_1_2_8_4_1","volume-title":"Transfusion Therapy: Clinical Principles and Practice","author":"Clark P.","year":"2011"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12363"},{"key":"e_1_2_8_6_1","first-page":"52","article-title":"Has the introduction of CMV untested blood components affected the rate of CMV PCR positivity in CMV negative adults receiving CMV negative allogeneic haematopoietic stem cell transplants?","volume":"109","author":"Evans R.","year":"2015","journal-title":"Vox Sanguinis"},{"key":"e_1_2_8_7_1","first-page":"130","article-title":"A study on the  incidence of CMV PCR positivity in adult CMV negative recipients receiving CMV negative donor allogeneic haematopoietic stem cell transplants","volume":"176","author":"Evans R.","year":"2017","journal-title":"British Journal of Haematology"},{"key":"e_1_2_8_8_1","first-page":"277","article-title":"Incidence of CMV infection in CMV-negative recipients of CMV\u2010negative hemopoietic stem cells since the change of transfusion policy to unscreened blood products","volume":"112","author":"Gamlath C. P.","year":"2017","journal-title":"Vox Sanguinis"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1438.2002.00020.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1182\/blood.V124.21.2894.2894","article-title":"Transfusion of CMV seronegative T\u2010deplete allogeneic stem cell transplant recipients with CMV unselected blood products confers a zero risk of CMV transmission in the era of universal leucodepletion: a UK single\u2010centre experience","volume":"124","author":"Hall S.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12219"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0042-9007.2004.00388.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.09.013"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu364"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365540110080412"},{"key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1182\/blood.V124.21.1140.1140","article-title":"High rates of passive CMV antibody acquisition pre\u2010allograft in patients receiving plasma\u2010rich CMV unselected and leukodepleted blood components: a caution for donor selection","volume":"124","author":"Lown R.N.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12264"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03739.x"},{"key":"e_1_2_8_19_1","volume-title":"Blood Transfusion: NICE Guidelines (NG24)","author":"National Institute for Health and Care Excellence","year":"2015"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03203.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2005.02.002"},{"key":"e_1_2_8_22_1","unstructured":"Walters G.(2016)NHSBT Portfolio of Blood Components and Guidance for their Clinical Use: NHS Blood and Transplant. URLhttp:\/\/hospital.blood.co.uk\/media\/28748\/spn223.pdf. (Accessed 27\/07\/17)."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02486.x"}],"container-title":["Transfusion Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftme.12461","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tme.12461","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T11:32:49Z","timestamp":1695555169000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tme.12461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,15]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/tme.12461"],"URL":"https:\/\/doi.org\/10.1111\/tme.12461","archive":["Portico"],"relation":{},"ISSN":["0958-7578","1365-3148"],"issn-type":[{"value":"0958-7578","type":"print"},{"value":"1365-3148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,15]]},"assertion":[{"value":"2016-05-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-08-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}